A novel class of cycloalkano[b]pyridines as potent and orally active opioid receptor-like 1 antagonists with minimal binding affinity to the hERG K+ channel.

A series of compounds based on 7-{[4-(2-methylphenyl)piperidin-1-yl]methyl}-6,7,8,9-tetrahydro-5 H-cyclohepta[ b]pyridine-9-ol ( (-)-8b), a potent and selective opioid receptor-like 1 (ORL1) antagonist, was prepared and evaluated using structure-activity relationship studies with the aim of removing its affinity to human ether-a-go-go related gene (hERG) K (+) channel. From these studies, 10l was identified as an optimized structure with respect to ORL1 antagonist activity, and affinity to the hERG K (+)channel. Furthermore, 10l showed good in vivo antagonism with a wide therapeutic index in regards to adverse cardiovascular effects.

[1]  D. Grandy,et al.  Orphanin FQ is a functional anti-opioid peptide , 1996, Neuroscience.

[2]  G. Bignan,et al.  Recent advances towards the discovery of ORL-1 receptor agonists and antagonists , 2005 .

[3]  C. Kozak,et al.  Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family , 1994, FEBS letters.

[4]  A. Levine,et al.  Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats , 1996, Neuroreport.

[5]  Y. Iwasawa,et al.  Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). , 1999, Journal of medicinal chemistry.

[6]  T. Miyata,et al.  cDNA cloning and regional distribution of a novel member of the opioid receptor family , 1994, FEBS letters.

[7]  Y. Iwasawa,et al.  In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. , 2000, European journal of pharmacology.

[8]  L. Terenius,et al.  Nociceptin/Orphanin FQ Microinjected into Hippocampus Impairs Spatial Learning in Rats , 1997, The European journal of neuroscience.

[9]  Y. Iwasawa,et al.  Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. , 2006, Journal of medicinal chemistry.

[10]  T. Hayama,et al.  6-Carboxy-5,7-diarylcyclopenteno[1,2-b]pyridine derivatives: a novel class of endothelin receptor antagonists. , 2002, Bioorganic & medicinal chemistry.

[11]  H. Champion,et al.  Nociceptin, an endogenous ligand for the ORL1 receptor, has novel hypotensive activity in the rat. , 1997, Life sciences.

[12]  H. Champion,et al.  Nociceptin, a novel endogenous ligand for the ORL1 receptor, has potent erectile activity in the cat. , 1997, The American journal of physiology.

[13]  Y. Kitao,et al.  4‐Aminoquinolines: Novel Nociceptin Antagonists with Analgesic Activity. , 2001 .

[14]  Z. Rankovic,et al.  Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.

[15]  N. Zaveri.  Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. , 2003, Life sciences.

[16]  I. Peretto,et al.  Lead generation and lead optimisation approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists , 2001 .

[17]  M. Sanguinetti,et al.  Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]. , 1994, The Journal of pharmacology and experimental therapeutics.

[18]  A. I. Brooks,et al.  Cloning and functional characterization through antisense mapping of a kappa 3-related opioid receptor. , 1995, Molecular pharmacology.

[19]  E. Prinssen,et al.  Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. , 2007, Current drug targets.

[20]  T. Manabe,et al.  Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors , 1998, Nature.

[21]  C. Evans,et al.  Orphanin FQ inhibits synaptic transmission and long‐term potentiation in rat hippocampus , 1997, Hippocampus.

[22]  H. Lippton,et al.  Nociceptin: an endogenous agonist for central opioid like1 (ORL1) receptors possesses systemic vasorelaxant properties. , 1997, Life sciences.

[23]  D. Grandy,et al.  Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor , 1995, Science.

[24]  C. George,et al.  Chemistry and pharmacology of the piperidine-based analogues of cocaine. Identification of potent DAT inhibitors lacking the tropane skeleton. , 1998, Journal of medicinal chemistry.

[25]  F. Monsma,et al.  Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G Vassart,et al.  ORL1, a novel member of the opioid receptor family , 1994, FEBS letters.

[27]  D. Lambert,et al.  Pharmacological characterization of the nociceptin / orphanin FQ receptor antagonist SB-612111: in vivo studies , 2007 .

[28]  M. Scheideler,et al.  Modification of Nociception and Morphine Tolerance by the Selective Orl-1 Antagonist Sb-612111 Running Title: Characterization of a Selective Orl-1 Antagonist , 2022 .